Recombinant Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (ab109543)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR259(2)] to IRS1 (phospho Y632)
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-IRS1 (phospho Y632) antibody [EPR259(2)]
See all IRS1 primary antibodies -
Description
Rabbit monoclonal [EPR259(2)] to IRS1 (phospho Y632) -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- 293T cell lysate
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.31% Sodium citrate, 0.175% Sodium chloride, 0.0172% EDTA, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR259(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab109543 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 132 kDa.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 132 kDa. |
Target
-
Function
May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. -
Involvement in disease
Polymorphisms in IRS1 may be involved in the etiology of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. -
Sequence similarities
Contains 1 IRS-type PTB domain.
Contains 1 PH domain. -
Post-translational
modificationsSerine phosphorylation of IRS1 is a mechanism for insulin resistance. Ser-312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor.
Phosphorylation of Tyr-896 is required for GRB2-binding. - Information by UniProt
-
Database links
- Entrez Gene: 3667 Human
- Omim: 147545 Human
- SwissProt: P35568 Human
- Unigene: 471508 Human
-
Alternative names
- HIRS 1 antibody
- HIRS1 antibody
- Insulin receptor substrate 1 antibody
see all
Images
-
All lanes : Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (ab109543) at 1/1000 dilution
Lane 1 : 293T cell lysate, untreated
Lane 2 : 293T cell lysate treated with Alkaline Phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 132 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab109543 has been referenced in 3 publications.
- Zong J et al. Bromodomain-containing protein 2 promotes lipolysis via ERK/HSL signalling pathway in white adipose tissue of mice. Gen Comp Endocrinol 281:105-116 (2019). PubMed: 31121164
- Zhang J et al. Establishment of a novel hepatic steatosis cell model by Cas9/sgRNA-mediated DGK? gene knockout. Mol Med Rep 17:2169-2176 (2018). PubMed: 29207074
- Song Q et al. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget 8:5003-5015 (2017). PubMed: 28002807